Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atro...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2021/05/15, Vol.60(10), pp.1533-1539 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1539 |
|---|---|
| container_issue | 10 |
| container_start_page | 1533 |
| container_title | Internal Medicine |
| container_volume | 60 |
| creator | Miyashita, Kaname Hongo, Yui Nakashima, Akihiko Kato, Seiya Kusano, Hironori Morizono, Shusuke Higashi, Nobuhiko |
| description | A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atrophy of the liver, and we detected HCV RNA in his serum using real time polymerase chain reaction. Furthermore, medical interviews showed that the patient had no episodes for acute HCV infection, but he did have a history of unspecified liver dysfunction. These findings support the possibility of the reactivation of seronegative occult HCV infection due to chemotherapy in a cancer patient. |
| doi_str_mv | 10.2169/internalmedicine.4768-20 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8188017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2461002903</sourcerecordid><originalsourceid>FETCH-LOGICAL-c610t-a859811d29fd1cbae465800ef4aa4ec222e202550a56b41c20d5bc6b1f987183</originalsourceid><addsrcrecordid>eNplks2O0zAQxyMEYsvCKyBLXLhksZ0vhwMS6rLsSkVdwYqrNXEnjavEDrZT1CfiNXFpqehy8Fhj_-Y_M_YkCWH0irOyfqdNQGegH3CllTZ4lVelSDl9ksxYltdpxbPiaTKjNYun0VwkL7zfUJqJqubPk4ssYzWLa5b8uoEAPbnFEYIO2pM5gTaKk3mHgw0dOhh3RBsC5D4SaAL5qUNHvkCv1waiu9gNY2cHeE_urfe66ZF8RVBBbyNvDbEt-YbOGlxHf4tkqdTUh7OM37WbPLkzLao_IdcTkmDPSniZPGuh9_jquF8mDzefHua36WL5-W7-cZGqktGQgihqwdiK1-2KqQYwLwtBKbY5QI6Kc46c8qKgUJRNzhSnq6JRZcPaWlRMZJfJh4PsODXxcVXs10EvR6cHcDtpQcvzG6M7ubZbKZgQlFVR4O1RwNkfE_ogB-0V9j0YtJOXPI91Ul7TLKJvHqEbO-1_NVJFVtRZZPaC4kApF5_XYXsqhlG5Hwb5eBjkfhgkpzH09b_NnAL__n4Elgdg4wOs8QSAC1r1-L9ySfdZoz2mOJGqAyfRZL8By1fWgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2535930337</pqid></control><display><type>article</type><title>Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><creator>Miyashita, Kaname ; Hongo, Yui ; Nakashima, Akihiko ; Kato, Seiya ; Kusano, Hironori ; Morizono, Shusuke ; Higashi, Nobuhiko</creator><creatorcontrib>Miyashita, Kaname ; Hongo, Yui ; Nakashima, Akihiko ; Kato, Seiya ; Kusano, Hironori ; Morizono, Shusuke ; Higashi, Nobuhiko</creatorcontrib><description>A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atrophy of the liver, and we detected HCV RNA in his serum using real time polymerase chain reaction. Furthermore, medical interviews showed that the patient had no episodes for acute HCV infection, but he did have a history of unspecified liver dysfunction. These findings support the possibility of the reactivation of seronegative occult HCV infection due to chemotherapy in a cancer patient.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.4768-20</identifier><identifier>PMID: 33191319</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Aged ; Ascites ; Atrophy ; Case Report ; Chemotherapy ; Hepacivirus - genetics ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Hepatitis C ; Hepatitis C - complications ; Hepatitis C - drug therapy ; hepatitis C virus reactivation ; Humans ; Infections ; Interferon ; Internal medicine ; Liver diseases ; Lymphoma ; Lymphoma - drug therapy ; Male ; malignant lymphoma ; occult hepatitis C virus infection ; Patients ; Polymerase chain reaction ; R-CHOP therapy ; Rituximab ; Rituximab - adverse effects ; Virus Activation</subject><ispartof>Internal Medicine, 2021/05/15, Vol.60(10), pp.1533-1539</ispartof><rights>2021 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2021</rights><rights>Copyright © 2021 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c610t-a859811d29fd1cbae465800ef4aa4ec222e202550a56b41c20d5bc6b1f987183</citedby><cites>FETCH-LOGICAL-c610t-a859811d29fd1cbae465800ef4aa4ec222e202550a56b41c20d5bc6b1f987183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188017/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188017/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33191319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyashita, Kaname</creatorcontrib><creatorcontrib>Hongo, Yui</creatorcontrib><creatorcontrib>Nakashima, Akihiko</creatorcontrib><creatorcontrib>Kato, Seiya</creatorcontrib><creatorcontrib>Kusano, Hironori</creatorcontrib><creatorcontrib>Morizono, Shusuke</creatorcontrib><creatorcontrib>Higashi, Nobuhiko</creatorcontrib><title>Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atrophy of the liver, and we detected HCV RNA in his serum using real time polymerase chain reaction. Furthermore, medical interviews showed that the patient had no episodes for acute HCV infection, but he did have a history of unspecified liver dysfunction. These findings support the possibility of the reactivation of seronegative occult HCV infection due to chemotherapy in a cancer patient.</description><subject>Aged</subject><subject>Ascites</subject><subject>Atrophy</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B virus</subject><subject>Hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>hepatitis C virus reactivation</subject><subject>Humans</subject><subject>Infections</subject><subject>Interferon</subject><subject>Internal medicine</subject><subject>Liver diseases</subject><subject>Lymphoma</subject><subject>Lymphoma - drug therapy</subject><subject>Male</subject><subject>malignant lymphoma</subject><subject>occult hepatitis C virus infection</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>R-CHOP therapy</subject><subject>Rituximab</subject><subject>Rituximab - adverse effects</subject><subject>Virus Activation</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplks2O0zAQxyMEYsvCKyBLXLhksZ0vhwMS6rLsSkVdwYqrNXEnjavEDrZT1CfiNXFpqehy8Fhj_-Y_M_YkCWH0irOyfqdNQGegH3CllTZ4lVelSDl9ksxYltdpxbPiaTKjNYun0VwkL7zfUJqJqubPk4ssYzWLa5b8uoEAPbnFEYIO2pM5gTaKk3mHgw0dOhh3RBsC5D4SaAL5qUNHvkCv1waiu9gNY2cHeE_urfe66ZF8RVBBbyNvDbEt-YbOGlxHf4tkqdTUh7OM37WbPLkzLao_IdcTkmDPSniZPGuh9_jquF8mDzefHua36WL5-W7-cZGqktGQgihqwdiK1-2KqQYwLwtBKbY5QI6Kc46c8qKgUJRNzhSnq6JRZcPaWlRMZJfJh4PsODXxcVXs10EvR6cHcDtpQcvzG6M7ubZbKZgQlFVR4O1RwNkfE_ogB-0V9j0YtJOXPI91Ul7TLKJvHqEbO-1_NVJFVtRZZPaC4kApF5_XYXsqhlG5Hwb5eBjkfhgkpzH09b_NnAL__n4Elgdg4wOs8QSAC1r1-L9ySfdZoz2mOJGqAyfRZL8By1fWgQ</recordid><startdate>20210515</startdate><enddate>20210515</enddate><creator>Miyashita, Kaname</creator><creator>Hongo, Yui</creator><creator>Nakashima, Akihiko</creator><creator>Kato, Seiya</creator><creator>Kusano, Hironori</creator><creator>Morizono, Shusuke</creator><creator>Higashi, Nobuhiko</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210515</creationdate><title>Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy</title><author>Miyashita, Kaname ; Hongo, Yui ; Nakashima, Akihiko ; Kato, Seiya ; Kusano, Hironori ; Morizono, Shusuke ; Higashi, Nobuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c610t-a859811d29fd1cbae465800ef4aa4ec222e202550a56b41c20d5bc6b1f987183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Ascites</topic><topic>Atrophy</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B virus</topic><topic>Hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>hepatitis C virus reactivation</topic><topic>Humans</topic><topic>Infections</topic><topic>Interferon</topic><topic>Internal medicine</topic><topic>Liver diseases</topic><topic>Lymphoma</topic><topic>Lymphoma - drug therapy</topic><topic>Male</topic><topic>malignant lymphoma</topic><topic>occult hepatitis C virus infection</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>R-CHOP therapy</topic><topic>Rituximab</topic><topic>Rituximab - adverse effects</topic><topic>Virus Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyashita, Kaname</creatorcontrib><creatorcontrib>Hongo, Yui</creatorcontrib><creatorcontrib>Nakashima, Akihiko</creatorcontrib><creatorcontrib>Kato, Seiya</creatorcontrib><creatorcontrib>Kusano, Hironori</creatorcontrib><creatorcontrib>Morizono, Shusuke</creatorcontrib><creatorcontrib>Higashi, Nobuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyashita, Kaname</au><au>Hongo, Yui</au><au>Nakashima, Akihiko</au><au>Kato, Seiya</au><au>Kusano, Hironori</au><au>Morizono, Shusuke</au><au>Higashi, Nobuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2021-05-15</date><risdate>2021</risdate><volume>60</volume><issue>10</issue><spage>1533</spage><epage>1539</epage><pages>1533-1539</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atrophy of the liver, and we detected HCV RNA in his serum using real time polymerase chain reaction. Furthermore, medical interviews showed that the patient had no episodes for acute HCV infection, but he did have a history of unspecified liver dysfunction. These findings support the possibility of the reactivation of seronegative occult HCV infection due to chemotherapy in a cancer patient.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>33191319</pmid><doi>10.2169/internalmedicine.4768-20</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2021/05/15, Vol.60(10), pp.1533-1539 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8188017 |
| source | MEDLINE; PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central |
| subjects | Aged Ascites Atrophy Case Report Chemotherapy Hepacivirus - genetics Hepatitis B Surface Antigens Hepatitis B virus Hepatitis C Hepatitis C - complications Hepatitis C - drug therapy hepatitis C virus reactivation Humans Infections Interferon Internal medicine Liver diseases Lymphoma Lymphoma - drug therapy Male malignant lymphoma occult hepatitis C virus infection Patients Polymerase chain reaction R-CHOP therapy Rituximab Rituximab - adverse effects Virus Activation |
| title | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A49%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatal%20Hepatitis%20C%20after%20Chemotherapy%20in%20a%20Patient%20with%20Malignant%20Lymphoma:%20Possible%20Reactivation%20of%20Seronegative%20Occult%20Hepatitis%20C%20Virus%20Infection%20Due%20to%20Chemotherapy&rft.jtitle=Internal%20Medicine&rft.au=Miyashita,%20Kaname&rft.date=2021-05-15&rft.volume=60&rft.issue=10&rft.spage=1533&rft.epage=1539&rft.pages=1533-1539&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.4768-20&rft_dat=%3Cproquest_pubme%3E2461002903%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2535930337&rft_id=info:pmid/33191319&rfr_iscdi=true |